Metastatic Renal Cell Carcinoma
Conditions
Keywords
sorafenib, pazopanib, cross-resistance, TKI, mRCC
Brief summary
* Retrospective studies showed Sorafenib's efficacy as second line treatment after a Tyrosine Kinase Inhibitor (TKI). * Currently there is no standard of treatment in 2nd line for patients treated in first line with pazopanib for metastatic Renal Cell Carcinoma (mRCC). * With this trial we evaluate the efficacy of sorafenib as second line of treatment in patients treated with pazopanib for mRCC.
Detailed description
* Retrospective studies showed Sorafenib's efficacy as second line treatment after a TKI: AXIS study showed sorafenib activity, in terms of Overall Response Rate (ORR), and the absence statistically significant difference in Overall Survival (OS) between the 2 arms, although there is a significant OS increase of 1.4 months in the Axitinib arm. The INTORSECT study (temsirolimus vs sorafenib in 2nd line after sunitinib) didn't demonstrate statistically significant difference for Progression Free Survival (PFS), but it showed an OS increase in patients treated with sorafenib. * The COMPARZ study demonstrated the non-inferiority of pazopanib vs sunitinib in 1st line of treatment for mRCC. * Currently there is no standard of treatment in 2nd line for patients treated in first line with pazopanib for mRCC. * Primary objective:to evaluate the efficacy of sorafenib (PFS) as second line of treatment in patients treated with pazopanib for mRCC. * Secondary objectives: To evaluate the safety of sorafenib in patients previously treated with pazopanib. To evaluate the Overall Survival. To evaluate the Quality of Life through specific questionnaires (FKSI-19; European Organization for Research and Treatment of Cancer quality of life questionnaire -C30).To assess the predictive role for PFS and OS of arterial blood pressure increase from baseline to week 4 and 8 after start of treatment with sorafenib. To assess the predictive role for PFS and OS of hand-foot syndrome before week 4 and 8 after start of treatment with sorafenib.
Interventions
DRUGSorafenib
Sorafenib 400 mg bid
Sponsors
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Patients with histological diagnosis of Renal Cell Carcinoma (RCC) * Measurable disease * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Life expectancy of at least 12 weeks. * Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening: * Hemoglobin \>= 10.0 g/dl * Absolute neutrophil count (ANC) \>1,500/mm3 * Platelet count \>= 100,000/ml * Total bilirubin ≤ 1.5 times the upper limit of normal * ALT and AST ≤ 2.5 x upper limit of normal * Alkaline phosphatase ≤ 4 x upper limit of normal * prothrombin time-international normalized ratio /partial thromboplastin time ≤ 1.5 x upper limit of normal \[Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.\] For patients on warfarin, close monitoring of at least weekly evaluations will be performed, until international normalized ratio is stable based on a measurement at pre-dose, as defined by the local standard of care. * Prognosis according to Heng: good or intermediate * Previous treatment with pazopanib * Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and two weeks after the completion of trial. * Signed informed consent must be obtained prior to any study specific procedures
Exclusion criteria
* First line treatment for metastatic RCC other than pazopanib. * History of cardiac disease: congestive heart failure \>New York Heart Association class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension (\>= 160 mmHg systolic and/or 90 mmHg diastolic). * History of HIV infection * Active clinically serious infections (\> grade 2 NCI-CTC version 3.0) * Brain or meningeal metastases * Patients with seizure disorder requiring medication (such as steroids or anti-epileptics) * History of organ allograft * Patients with evidence or history of bleeding diathesis * Patients undergoing renal dialysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival (months) of patients treated with sorafenib after progression to pazopanib | 24 months |
Secondary
| Measure | Time frame |
|---|---|
| Safety profile of sorafenib using Common Terminology Criteria for Adverse Events (CTCAE) criteria v.4.0 in patients previously treated with pazopanib | 24 months |
| Overall Survival (months) of patients treated with sorafenib after pazopanib progression | 24 months |
| Quality of Life of patients treated with sorafenib after pazopanib progression using the specific questionnaires FKSI-19 and European Organization for Research and Treatment of Cancer quality of life questionnaire -C30. | 24 months |
Countries
Italy
Outcome results
None listed